Thrombolytic Therapy in Acute Ischemic Stroke Study, Part A "TTAISS"


Phase 2 Results


There was no difference between treatment groups but the placebo group had a better outcome in terms of the planned primary and secondary neurological and functional outcomes at 30 and 90 days. Treatment with rt-PA significantly increased the rate of symptomatic intracerebral hemorrhage within 10 days (11% vs. 0%, p<0.01) and mortality at 90 days (23% vs. 7%, p<0.01).